Technical Analysis for GHDX - Genomic Health, Inc.

Grade Last Price % Change Price Change
grade D 56.39 0.36% 0.20
GHDX closed up 1.9 percent on Thursday, July 18, 2019, on 49 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Earnings due: Aug 1

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Down
See historical GHDX trend table...

Date Alert Name Type % Chg
Crossed Above 50 DMA Bullish 0.36%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.36%
Outside Day Range Expansion 0.36%
Fell Below 50 DMA Bearish 2.27%
Fell Below 20 DMA Bearish 0.61%
MACD Bearish Signal Line Cross Bearish 0.61%
50 DMA Support Bullish 0.61%
20 DMA Support Bullish -1.42%
50 DMA Support Bullish -1.42%
20 DMA Support Bullish 0.20%

Older signals for GHDX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Genomic Health, Inc., a healthcare company, provides actionable genomic information to personalize cancer treatment decisions. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. The company provides the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the likelihood of breast cancer recurrence and the likelihood of chemotherapy benefit. It also offers the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy. In addition, the company provides the Oncotype DX tests for patients with ductal carcinoma in situ, a pre-invasive form of breast cancer. Genomic Health, Inc. was founded in 2000 and is headquartered in Redwood City, California.
Medicine Cancer Healthcare Clinical Medicine Treatment Of Cancer Chemotherapy Breast Cancer Cancer Treatment Colorectal Cancer
Is GHDX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 92.18
52 Week Low 50.77
Average Volume 491,794
200-Day Moving Average 67.0904
50-Day Moving Average 55.2384
20-Day Moving Average 56.628
10-Day Moving Average 56.812
Average True Range 1.9878
ADX 16.97
+DI 19.3014
-DI 21.4927
Chandelier Exit (Long, 3 ATRs ) 54.5366
Chandelier Exit (Short, 3 ATRs ) 58.5934
Upper Bollinger Band 60.2979
Lower Bollinger Band 52.9581
Percent B (%b) 0.44
BandWidth 12.961433
MACD Line 0.2018
MACD Signal Line 0.365
MACD Histogram -0.1632
Fundamentals Value
Market Cap 1.94 Billion
Num Shares 34.5 Million
EPS -0.15
Price-to-Earnings (P/E) Ratio -374.60
Price-to-Sales 3.41
Price-to-Book 6.72
PEG Ratio -149.73
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 59.43
Resistance 3 (R3) 59.19 57.87 58.89
Resistance 2 (R2) 57.87 57.04 57.99 58.71
Resistance 1 (R1) 57.03 56.54 57.45 57.27 58.53
Pivot Point 55.71 55.71 55.92 55.83 55.71
Support 1 (S1) 54.87 54.88 55.29 55.11 53.85
Support 2 (S2) 53.55 54.38 53.67 53.67
Support 3 (S3) 52.71 53.55 53.49
Support 4 (S4) 52.95